MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Kymera Therapeutics Inc

Open

BrancheGesundheitswesen

33.1 1.91

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

32.02

Max

33.81

Schlüsselkennzahlen

By Trading Economics

Einkommen

-8.3M

-71M

Verkäufe

3.7M

7.4M

EPS

-0.89

Gewinnspanne

-956.884

Angestellte

188

EBITDA

-8.3M

-69M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+80.98% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

9. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-523M

1.8B

Vorheriger Eröffnungskurs

31.19

Vorheriger Schlusskurs

33.1

Technischer Score

By Trading Central

Vertrauen

Very Strong Bullish Evidence

Kymera Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

1. Nov. 2024, 03:00 UTC

Top News

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ

9. Juli 2024, 09:05 UTC

Top News

These Stocks Are Moving the Most Today: Tesla, Corning, BP, Intel, and More -- Barrons.com

Peer-Vergleich

Kursveränderung

Kymera Therapeutics Inc Prognose

Kursziel

By TipRanks

80.98% Vorteil

12-Monats-Prognose

Durchschnitt 55.56 USD  80.98%

Hoch 72 USD

Tief 49 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Kymera Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

11 ratings

10

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

25.43 / N/AUnterstützung & Widerstand

Kurzfristig

Very Strong Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Strong Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.